Article Details

Eisai, in pricing new Alzheimer's drug, tries to sidestep controversy | BioPharma Dive

Retrieved on: 2023-01-07 19:10:49

Tags for this article:

Click the tags to see associated articles and topics

Eisai, in pricing new Alzheimer's drug, tries to sidestep controversy | BioPharma Dive. View article details on hiswai:

Excerpt

The pharma set the average cost of it and Biogen's newly approved medicine Leqembi to $26,500 per year. Published Jan. 6, 2023.

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up